Baxios

Baxios is a biotechnology company focused on developing novel therapeutics that target the Bax protein to induce apoptosis in cancer cells. The company's primary focus is on oncology, specifically targeting solid tumors through the modulation of cell death pathways. Baxios utilizes a proprietary platform to identify and develop small molecules and peptides that can effectively activate or inhibit Bax, depending on the therapeutic need. Currently in the pre-clinical stage, the company is working to advance its lead candidates toward clinical trials. Baxios aims to provide more effective and targeted treatment options for patients with various forms of cancer.